glp-1 agonist drugs oral receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is GLP-1 medicines started with injectable

While lifestyle modifications such as dietary changes, increased physical activity, and behavioral therapy remain the foundation of treatment, their long-term effectiveness is often limited, especially in cases of severe obesity

We present this article in accordance with the Narrative Review reporting checklist (available at Methods A search of the literature was conducted on OVID (1947May 2025) using the terms [papilledema OR intracranial hypertension OR idiopathic intracranial hypertension OR brain pseudotumor] AND [glucagon like peptide 1 OR glucagon like peptide 1 receptor agonist OR semaglutide OR exendin 4 OR liraglutide OR tirzepatide]

Lancet (London, England)

At 12 weeks, Semaglutide typically produces 5-6% weight loss